H2 Blockers For Stress Ulcer Prophylaxis In Icu Settings

by

Stress ulcers are a common complication in critically ill patients admitted to intensive care units (ICUs). They can lead to significant gastrointestinal bleeding, increasing morbidity and mortality. Prophylactic use of medications helps prevent the development of these ulcers, with H2 blockers being a popular choice.

Understanding Stress Ulcers in ICU Patients

Stress ulcers, also known as stress-related mucosal disease, develop due to physiological stress, hypoperfusion of the gastrointestinal mucosa, and increased acid production. Patients in ICU are particularly vulnerable due to factors such as mechanical ventilation, coagulopathy, and severe illness.

Role of H2 Blockers in Stress Ulcer Prophylaxis

H2 receptor antagonists, or H2 blockers, reduce gastric acid secretion by blocking histamine H2 receptors on parietal cells in the stomach lining. This decrease in acid helps prevent mucosal injury and bleeding in high-risk ICU patients.

Common H2 Blockers Used in ICU Settings

  • Ranitidine (withdrawn in some markets due to safety concerns)
  • Famotidine
  • Nizatidine
  • Cimetidine

Indications for H2 Blocker Use

  • Patients on mechanical ventilation for more than 48 hours
  • Patients with coagulopathy or bleeding disorders
  • History of gastrointestinal bleeding
  • Multiple trauma or severe burns
  • Severe head injury

Administration and Dosing

H2 blockers are typically administered intravenously or orally, depending on the patient’s condition. Dosing varies based on the specific medication and patient factors. For example, famotidine IV is commonly given as 20 mg once or twice daily.

Potential Risks and Considerations

While effective, H2 blockers may carry risks such as increased susceptibility to infections like pneumonia, nutrient malabsorption, and potential drug interactions. Careful assessment is necessary before initiation, especially in patients with renal impairment.

Conclusion

H2 blockers are a valuable tool in the prevention of stress-related mucosal bleeding in ICU patients. Their use should be guided by clinical risk factors, and ongoing assessment is essential to balance benefits and potential adverse effects.